BioPharmX Corporation (BPMX) News
Filter BPMX News Items
BPMX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest BPMX News From Around the Web
Below are the latest news stories about BioPharmX Corp that investors may wish to consider to help them evaluate BPMX as an investment opportunity.
BioPharmX Announces 1-for-12 Reverse Stock Split Merger Transaction Expected to Close on May 18, 2020BioPharmX Corporation (NYSE American: BPMX) ("BioPharmX" or the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that, in anticipation of closing its merger with Timber Pharmaceuticals, it will effect a 1-for-12 reverse stock split of its outstanding common stock. The reverse stock split is expected to be effective for trading purposes as of the commencement of trading on Tuesday, May 19, 2020. |
The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse MergerHere's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs May 13.) … |
BioPharmX Corporation Announces Approval of Merger by Stockholders at Special MeetingCAMPBELL, Calif., May 13, 2020 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) ("BioPharmX") today announced that all proposals related to its proposed merger with Timber Pharmaceuticals LLC ("Timber") were approved by BioPharmX's stockholders at a special meeting held on May… |
BioPharmX Corporation Urges Stockholders to Vote Now on Proposed Merger with Timber PharmaceuticalsCAMPBELL, Calif., May 8, 2020 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) ("BioPharmX") is urging its stockholders to vote now on the proposed merger of BioPharmX with Timber Pharmaceuticals LLC ("Timber") and related matters as described in the proxy statement/prospectus…. |
BioPharmX And Timber Pharmaceuticals Announce Entry into Merger AgreementSAN JOSE, Calif. and WOODCLIFF LAKE, N.J., Jan. 28, 2020 /PRNewswire/ --BioPharmX Corporation (NYSE American: BPMX) ("BioPharmX") and Timber Pharmaceuticals LLC ("Timber"), a privately held biopharmaceutical company focused on the development and commercialization of treatments for orphan… |
BioPharmX Reports Fiscal Third Quarter 2020 Financial Results and Provides Corporate UpdateSAN JOSE, Calif., Dec. 10, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the fiscal quarter ended October 31, 2019. Corporate Update In… |
The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax OfferingHere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 7) Akero Therapeutics Inc (NASDAQ: AKRO ) Allakos Inc (NASDAQ: ALLK ) Cytokinetics, Inc. (NASDAQ: CYTK ) Guardant Health Inc (NASDAQ: GH ) (reacted to strong second-quarter results) Morphic Holding Inc (NASDAQ: MORF ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 7) ABIOMED, Inc. (NASDAQ: ABMD ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioCardia Inc (NASDAQ: BCDA ) BIOLINERX LTD/S ADR (NASDAQ: BLRX ) Biopharmx Corp NYSE: (BPMX) CAN-FITE BIOPHA/S ADR (NYSE: CANF ) CELLECT BIOTECH/S ADR (NASDAQ: A... |
The Daily Biotech Pulse: Roche's Flu Drug Aces Late-Stage Trial, Acura Outlicenses Pain Medication, Neuronetics Gets New Finance ChiefHere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 2) ANI Pharmaceuticals Inc Common Stock (NASDAQ: ANIP ) ArQule, Inc. (NASDAQ: ARQL ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Coherus Biosciences Inc (NASDAQ: CHRS ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) MeiraGTx Holdings PLC (NASDAQ: MGTX ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 2) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Atreca Inc (NASDAQ: BCEL )(IPOed June 20) Biopharmx Corp (NYSE: BPMX ) ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Nuvectra Corp (NASDAQ: NVTR ) Personalis Inc (NASDAQ: PSNL ) (IPOed... |
The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to DepartHere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 25) ArQule, Inc. (NASDAQ: ARQL ) Zai Lab Ltd (NASDAQ: ZLAB ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 25) AbbVie Inc (NYSE: ABBV )(announced a deal to buy Allergan plc (NYSE: AGN ) for $63 billion) Acer Therapeutics Inc (NASDAQ: ACER )(The FDA issued complete response letter to its rare disease drug Edsivo) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aldeyra Therapeutics Inc (NASDAQ: ALDX )( reported negative results for the late-stage study that evaluated its reproxalap in anterior uveitis) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Axcella Health Inc (NASDAQ: AXLA ) Biopharmx Corp NYSE: (BPMX) (reported positive results fo... |
BioPharmX Announces Last Patient Visit in Phase 2b Trial of BPX-04 for Papulopustular RosaceaSAN JOSE, Calif., May 22, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, announced today that the last patient in the Company's Phase 2b clinical trial of BPX-041, a novel topical gel formulation of fully solubilized minocycline for the treatment of papulopustular rosacea, has completed their last clinical visit. "We are pleased to announce this important milestone and look forward to reporting topline results from the study in early July 2019, subject to successful database lock and results validation," said Dr. David S. Tierney, BioPharmX Chief Executive Officer. The randomized, double-blind, vehicle-controlled study enrolled 206 subjects with moderate-to-severe papul... |